Education
About Us
Working with TipRanks
Follow Us
Autolus Therapeutics (AUTL)
:AUTL
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.26Last Year’s EPS
-0.24Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 20, 2025
|% Change Since: -11.86%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive sentiment, highlighting the successful U.S. launch of AUCATZYL, strong financial backing, and promising clinical data. However, financial challenges remain with increased operating and net losses, as well as high R&D expenditures.Company Guidance
During the Autolus Therapeutics call discussing the full year 2024 financial results and business updates, several key metrics were highlighted. The company reported cash, cash equivalents, and marketable securities totaling $588 million at the end of 2024, which was an increase from $239 million at the end of 2023, primarily due to a $600 million collaboration with BioNTech. The loss from operations for 2024 was $241.4 million, compared to $179.7 million in 2023. The commercial launch of AUCATZYL in the U.S. was a primary focus, with 33 centers authorized as of March 19, 2025, expected to reach approximately 60% of the target patient population. Autolus aims to onboard about 60 centers by year-end, covering the majority of U.S. patients. The company received a $30 million milestone payment from Blackstone following FDA approval of AUCATZYL, and ongoing regulatory processes in the UK and EU are expected to yield decisions in the second half of 2025. The call also addressed the upcoming R&D event on April 23, 2025, in New York, where further details on expanding the utility of obe-cel and other product candidates will be shared.Successful Commercial Launch of AUCATZYL
The commercial launch of AUCATZYL in the U.S. is progressing well, with 33 centers authorized as of March 19, covering approximately 60% of the target patient population. The company expects to have 60 centers by year-end, potentially covering the majority of U.S. patients.
U.S. Approval and Positive Label for obe-cel
Obe-cel was approved in the U.S. on November 8, slightly ahead of schedule, with a favorable label for relapsed refractory ALL in adult patients and without a REMS program, indicating a strong foundation for commercial use.
Strong Financial Position
Added $600 million to the balance sheet through collaboration with BioNTech and public financing, resulting in a cash position of $588 million at year-end 2024, compared to $239 million at the end of 2023.
Positive Clinical Data
Published clinical results in the New England Journal of Medicine, showing high clinical activity and an attractive safety profile of obe-cel, with low levels of high-grade CRS and ICANS.
Strategic Milestone Payments
Received $30 million milestone payment from Blackstone following FDA approval, demonstrating financial support and collaboration success.
---
AUTL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AUTL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 20, 2025 | $1.94 | $1.68 | -13.40% |
| Nov 12, 2024 | $3.51 | $3.33 | -5.13% |
| Aug 08, 2024 | $4.02 | $3.64 | -9.45% |
| May 17, 2024 | $4.07 | $4.39 | +7.86% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Autolus Therapeutics (AUTL) report earnings?
Autolus Therapeutics (AUTL) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Autolus Therapeutics (AUTL) earnings time?
Autolus Therapeutics (AUTL) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AUTL EPS forecast?
AUTL EPS forecast for the fiscal quarter 2025 (Q1) is -0.26.
---